Indonesia gets 1.8 million doses of Sinovac Biotech COVID-19 vaccine

Published On 2021-01-03 03:45 GMT   |   Update On 2021-01-03 03:45 GMT

Jakarta: A total of 1.8 million doses of Covid-19 vaccine made by the Chinese biopharmaceutical company Sinovac Biotech arrived in Indonesia on Thursday, according to Indonesian government officials. Foreign Minister Retno Marsudi said this is the second batch of the Sinovac vaccine delivery for Indonesia, and the first batch of 1.2 million doses arrived on December 6, the Xinhua news...

Login or Register to read the full article

Jakarta: A total of 1.8 million doses of Covid-19 vaccine made by the Chinese biopharmaceutical company Sinovac Biotech arrived in Indonesia on Thursday, according to Indonesian government officials.

Foreign Minister Retno Marsudi said this is the second batch of the Sinovac vaccine delivery for Indonesia, and the first batch of 1.2 million doses arrived on December 6, the Xinhua news agency reported.

"With this arrival, it means that there are already 3 million doses of Sinovac vaccine in Indonesia," Marsudi told a virtual press conference.

Health Minister Budi Gunadi Sadikin said vaccination is one of Indonesia's main strategies to fight the Covid-19 pandemic, adding, "It would take more than 12 months to complete the vaccination program, so we always keep up to health protocols."

Indonesia is planning to vaccinate 181.5 million of its population in 2021 in order to achieve herd immunity and break the chain of coronavirus transmissions.

Read also: Two million doses of AstraZeneca COVID vaccine set to be supplied every week by mid-January in UK: Report

The first period of vaccination will be from January to April 2021, for inoculating 1.3 million medical workers, 17.4 million public workers, and 21.5 million elderly people.

The second period will run from April 2021 to March 2022 for vaccination of 63.9 million vulnerable people and 77.4 million people of other groups.

Read also: Indonesia to strike vaccine deals with Pfizer, AstraZeneca



Tags:    
Article Source : IANS

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News